NIH: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U19 Clinical Trial Optional)

This FOA encourages applications to advance the discovery, preclinical development, and proof of concept testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders or alcohol use disorders, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.

Deadline: July 27, 2020

More information.